Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016
about
Sarcopaenia and rheumatoid arthritis.Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.Establishment and characterization of a novel murine model of pancreatic cancer cachexia.Single-nucleotide polymorphisms in cachexia-related genes: Can they optimize the treatment of cancer cachexia?Syngeneic B16F10 Melanoma Causes Cachexia and Impaired Skeletal Muscle Strength and Locomotor Activity in Mice.Considering technique of assessment and method for normalizing skeletal muscle mass.The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice.Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients.A muscle-specific MuRF1-E2 network requires stabilization of MuRF1-E2 complexes by telethonin, a newly identified substrate.An analysis of the types of recently published research in the field of cachexia.Managing the nutritional needs of palliative care patients.Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017.Wasting away: How to treat cachexia and muscle wasting in chronic disease?More variety with the Journal of Cachexia, Sarcopenia and Muscle: JCSM Clinical Reports and JCSM Rapid Communications have both gone live.Increased gut permeability in cancer cachexia: mechanisms and clinical relevance.Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation.The Relation between Sarcopenia and Mortality in Patients at Intensive Care Unit.Collagen-induced arthritis as an animal model of rheumatoid cachexia.Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018Klebsiella oxytoca expands in cancer cachexia and acts as a gut pathobiont contributing to intestinal dysfunction
P2860
Q30234376-6D1A0B36-B52D-4FC1-812D-32A94D8DB862Q38636513-B03B2983-C70F-4A9B-A616-B095EC77F329Q38653925-16D67FC0-A52A-4518-9E65-AA9D045EF789Q42336582-F755CBB0-5372-4974-A333-5257D2AE18BFQ42369823-C3588B3D-9728-45FC-97AE-7949E6C90E4FQ43549750-F6767C57-AEA6-40BF-8745-35DD8A6F142AQ47117911-8290EE1D-EB52-42C0-BE5C-017CCCB11792Q47217492-C8CA0F7B-9EFF-4B6F-9817-4A3DAD09D5F7Q47261247-7B2665EC-B5A2-47D9-988D-F8D61278636CQ47568983-91CC4AEF-85EC-4095-BD17-0AFCA853A0EAQ47601526-7BFE1134-D3FD-4510-A289-27314D31B3E9Q47625103-D01398F4-6D10-4F47-A297-EFA285371333Q47664420-B776B047-5A2F-44D3-9F52-52E961F55407Q48743369-6C5E250E-7CDF-4412-9AA2-C3C1A2D848F9Q52806155-3B36A9C0-AECA-4D9E-8E6D-9CAB4A67D187Q53688957-F81C17EE-5128-43D3-AA47-EB9C7A30A9FEQ54504436-B806D34C-F2E8-4569-B2DF-4855CC1AC58DQ54957754-F6039D06-1DDC-4693-A8BB-4A299E5AF07AQ55319050-9E5485AE-8F6C-42CD-91F8-DB87734A5A90Q57476138-91A8CBBB-B623-4550-9BD3-1E828DD3F42AQ58770854-320EEE33-A17C-4D97-BBA4-B96C6F4600EB
P2860
Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Prevalence and clinical impact ...... facts and numbers update 2016
@en
Prevalence and clinical impact ...... facts and numbers update 2016
@nl
type
label
Prevalence and clinical impact ...... facts and numbers update 2016
@en
Prevalence and clinical impact ...... facts and numbers update 2016
@nl
prefLabel
Prevalence and clinical impact ...... facts and numbers update 2016
@en
Prevalence and clinical impact ...... facts and numbers update 2016
@nl
P2860
P356
P1476
Prevalence and clinical impact ...... facts and numbers update 2016
@en
P2093
Markus S Anker
P2860
P304
P356
10.1002/JCSM.12167
P577
2016-11-02T00:00:00Z